The second (RADIUS) is an ongoing, randomized, open-label, phase 2 trial evaluating the addition of midostaurin to standard of care vs. standard of care alone in the post-transplant setting in patients with FLT3-mutated AML who underwent alloHSCT and have not relapsed (NCT01883362). The gene discussed is FLT3; the disease is acute myeloid leukemia.